PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)

Benzer Materyaller

• Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
  Yazar:: Madlen Jentzsch, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-12-01)
• P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
  Yazar:: Lara Bischof, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
  Yazar:: Madlen Jentzsch, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
  Yazar:: Sebastian Schwind, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-03-01)
• Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
  Yazar:: Dominic Brauer, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-03-01)